Prusogliptin Explained
| Legal Status: | Investigational |
| Synonyms: | DBPR108 |
| Cas Number: | 1186426-66-3 |
| Pubchem: | 44201003 |
| Unii: | E329HG23ZT |
| Chembl: | 1082462 |
| Chemspiderid: | 24662486 |
| Iupac Name: | (2S,4S)-4-Fluoro-1-[2-[(2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile |
| Stdinchi: | 1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1 |
| Stdinchikey: | VQKSCYBKUIDZEI-STQMWFEESA-N |
| Smiles: | CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@H](C[C@H]2C#N)F |
| C: | 16 |
| H: | 25 |
| F: | 1 |
| N: | 4 |
| O: | 2 |
Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.[1] [2] [3]
Notes and References
- Xu . Jianping . Ling . Hongwei . Geng . Jianlin . Huang . Yanli . Xie . Ying . Zheng . Huiping . Niu . Huikun . Zhang . Tianhao . Yuan . Jing . Xiao . Xinhua . Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial . Diabetes, Obesity and Metabolism . November 2022 . 24 . 11 . 2232–2240 . 10.1111/dom.14810. 35791646 . 9796963 .
- Yeh . Kai-Chia . Yeh . Teng-Kuang . Huang . Chung-Yu . Hu . Chih-Bo . Wang . Min-Hsien . Huang . Yu-Wen . Chou . Ling-Hui . Ho . Hsuan-Hui . Song . Jen-Shin . Hsu . Tsu . Jiaang . Weir-Torn . Chao . Yu-Sheng . Chen . Chiung-Tong . DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity . Life Sciences . August 2021 . 278 . 119574 . 10.1016/j.lfs.2021.119574. 33961850 . 233999305 .
- Wang . Wei . Yao . Jun . Guo . Xiaohui . Guo . Yushan . Yan . Chaoli . Liu . Kuanzhi . Zhang . Ying . Wang . Xiaoyue . Li . Hongmei . Wen . Zhongyuan . Wang . Xinling . Li . Shuangqing . Xiao . Xinhua . Liu . Weijuan . Li . Ziling . Zhang . Lihui . Shao . Shiying . Ye . Shandong . Qin . Guijun . Li . Yiming . Li . Feng . Zhang . Xiaomei . Li . Xuefeng . Peng . Yongde . Deng . Hongyan . Xu . Xiangjin . Zhou . Ligang . Huang . Yanli . Cao . Mengya . Xia . Xuefang . Shi . Mingbiao . Dou . Jing . Yuan . Jing . Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial . Current Medical Research and Opinion . 2 July 2020 . 36 . 7 . 1107–1115 . 10.1080/03007995.2020.1761311. 32338063 . 216555956 .
